Evaluation of Cu-PTSM as a tracer of tumor perfusion: Comparison with labeled microspheres in spontaneous canine neoplasms
References (24)
- et al.
Correlation of Cu(PTSM) localization with regional blood flow in the heart and kidney
Nucl. Med. Biol.
(1989) - et al.
Development and validation of a solvent extraction technique for determination of Cu-PTSM in blood
Nucl. Med. Biol.
(1993) - et al.
Investigation of copper-PTSM as a PET tracer for tumor blood flow
Nucl. Med. Biol.
(1991) - et al.
An evaluation of Cu-64 pyruvaldehyde bis(methylthiosemicarbazone) (PTSM) for the measurement of tissue perfusion
J. Nucl. Med.
(1989) - et al.
The kinetics of copper-62-PTSM in the normal human heart
J. Nucl. Med.
(1992) - et al.
Relationship between size and perfusion rate of transplanted tumors
J. Natl Cancer Inst.
(1962) - et al.
Abnormal response of tumor vasculature to vasoactive drugs
J. Natl Cancer Inst.
(1984) - et al.
Distribution of blood flow in the dog kidney
Acta Physiol. Scand.
(1979) - et al.
Relationship between autoradiographically measured blood flow and ATP concentrations obtained from imaging bioluminescence in tumors following hyperthermia
Int. J. Cancer
(1993) - et al.
Relative error and variability in blood flow measurements with radiolabeled microspheres
Am. J. Physiol.
(1982)
[62Cu]-labeled pyruvaldehyde bis(N4-methylthiosemicarbazonato) copper(II): synthesis and evaluation as a positron emission tomography tracer for cerebral and myocardial perfusion
J. Nucl. Med.
PET in clinical oncology
Cancer Metastasis Rev.
Cited by (26)
Synthesis and formulation of [<sup>64</sup>Cu]Cu-PTSM for PET perfusion imaging in small animal models
2022, Applied Radiation and IsotopesCitation Excerpt :Radiocopper-labeled Cu-PTSM shows high first-pass cerebral extraction and radionuclide retention (Green et al., 1988; Mathias et al., 1990), as well as high extraction and retention in myocardium over a broad flow range (Shelton et al., 1989; Barnhart et al., 1989; Shelton et al., 1990; Herrero et al., 1993), without sensitivity to underlying myocardial hypoxia. Cu-PTSM has similarly been shown to be suitable for PET assessment of renal perfusion (Barnhart et al., 1989; Shelton et al., 1990) and tumor perfusion (Mathias et al., 1991; Mathias et al., 1994) in animal models. Unfortunately, in contrast to its behavior in animal models, the Cu-PTSM chelate strongly associates with Warfarin binding site of human serum albumin (HSA) (Mathias et al., 1995; Basken et al., 2008; Basken et al., 2009; Basken and Green, 2009).
Clinical imaging of hypoxia: Current status and future directions
2018, Free Radical Biology and MedicineCitation Excerpt :Prior to use for hypoxia, most the initial investigations into thiosemicarbazones and their metal complexes focused on their role in the treatment of a variety of diseases including bacterial and viral infections, malaria and cancer [349,350]. The bisthiosemicarbazone 62Cu-PTSM (copper pyruvaldehyde-bis(N4-methylthiosemicarbazone)) has been investigated extensively as a blood perfusion tracer, particularly for myocardial and neurological purposes [351–368]. Work by Fujibayashi and co-workers in 1997 showed that CuATSM (copper diacetyl-bis(N4-methylthiosemicarbazone)), which differs by only a methyl group on the backbone, had statistically significant hypoxic selectivity in ex vivo ischaemic rat heart models [369,370].
Positron emission tomography (PET) assessment of renal perfusion
2011, Seminars in NephrologyCitation Excerpt :Compounds such as Cu-PTSM and Cu-ETS (Fig. 3) show the desired high first-pass extraction of tracer, along with prolonged “microsphere-like” tissue retention of the radiolabel12,33,36-39 as these chelates undergo rapid intracellular reductive decomposition (liberating the 62Cu radiolabel to the endogenous cellular copper pool40-43). The lead Cu-PTSM radiopharmaceutical showed significant potential as a multi-organ tracer for flow quantification (mL · min−1 · g−1) in a variety of animal models28,34,44,45 and also has been studied in human beings.28,35,39,46-49 Unfortunately, in contrast to its behavior in animal models, Cu-PTSM strongly associates with the warfarin binding site of human serum albumin,50-53 making its tissue extraction fraction strongly perfusion-rate–dependent in human beings and undermining clinical use for robust flow quantification.
Bifunctional coupling agents for radiolabeling of biomolecules and target-specific delivery of metallic radionuclides
2008, Advanced Drug Delivery ReviewsAssessment of Cu-ETS as a PET radiopharmaceutical for evaluation of regional renal perfusion
2007, Nuclear Medicine and BiologyImaging hypoxia in tumors
2001, Seminars in Nuclear Medicine